Crescent Biopharma CFO sells 568 shares at $17.90

CBIO’s chief financial officer reported an automatic sale of shares to cover taxes from restricted stock unit vesting under a Rule 10b5-1 plan.

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Financial Officer Richard William Scalzo sold 568 Ordinary Shares on September 16, 2026 in an open-market transaction at a weighted average price of $17.90 per share. The shares were automatically sold to satisfy tax withholding obligations from vesting restricted stock units under a Rule 10b5-1 trading instruction. Following this sale, he directly holds 19,730 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 568 shares

Net Sell 1 txn

Insider Scalzo Richard William

Role Chief Financial Officer

Sold 568 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	568	$17.90	$10K

Holdings After Transaction: Ordinary Shares — 19,730 shares (Direct)

Footnotes (2)

1. F1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Shares sold: 568 shares Weighted average sale price: $17.90 per share Post-transaction holdings: 19,730 shares +3 more

6 metrics

Shares sold 568 shares Ordinary Shares sold on September 16, 2026

Weighted average sale price $17.90 per share Average price for 568 shares sold on September 16, 2026

Post-transaction holdings 19,730 shares Ordinary Shares directly held by the CFO after the sale

Sale price range $17.10–$19.17 per share Price range of multiple transactions included in the weighted average

Rule 10b5-1 instruction adoption date February 25, 2026 Date the trading instruction covering these tax sales was adopted

RSU grant date December 15, 2025 Grant date of restricted stock units whose vesting triggered tax sales

Key Terms

Rule 10b5-1 instruction, restricted stock units, weighted average price, tax withholding obligations

4 terms

Rule 10b5-1 instruction regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted"

restricted stock units financial

"in connection with the settlement of restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

tax withholding obligations financial

"sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CBIO’s chief financial officer report?

CRESCENT BIOPHARMA’s Chief Financial Officer Richard William Scalzo reported selling 568 Ordinary Shares on September 16, 2026. The filing states the shares were automatically sold to satisfy tax withholding obligations related to vesting restricted stock units.

At what price were the CBIO shares sold in this Form 4 filing?

The Form 4 reports a weighted average price of $17.90 per share for the 568 Ordinary Shares sold. A footnote explains the shares were sold in multiple transactions between $17.10 and $19.17 per share.

How many CBIO shares does the CFO hold after this reported sale?

After the reported sale, Chief Financial Officer Richard William Scalzo directly holds 19,730 Ordinary Shares of CRESCENT BIOPHARMA, INC. as shown in the post-transaction holdings figure on the Form 4.

Was the CBIO insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 instruction adopted by Richard William Scalzo on February 25, 2026, solely to cover taxes from vesting restricted stock units.

Why did the CBIO CFO sell 568 shares according to the Form 4?

The Form 4 explains the 568 shares were automatically sold to satisfy tax withholding obligations arising from the settlement of restricted stock units granted to the CFO on December 15, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:03 PM Accepted by SEC EDGAR 09/18/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scalzo Richard William

(Last) (First) (Middle)

C/O CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/16/2026		S		568(1)	D	$17.9(2)	19,730	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Remarks:

	/s/ Barbara Bispham Hale, as attorney-in-fact for Richard William Scalzo	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)